布地奈德/福莫特罗吸入剂对支气管扩张症患者NF-<i>κ</i>B通路的影响以及疗效分析

符汉光

doi:10.13201/j.issn.1009-5918.2018.04.015

布地奈德/福莫特罗吸入剂对支气管扩张症患者NF-κB通路的影响以及疗效分析

符汉光^,

- 海南医学院第二附属医院急诊科(海口, 570311)

详细信息

通讯作者: 符汉光, E-mail:13876909539@163.com

中图分类号: R562.22

收稿日期: 2017-12-11

Effect of Budesonide and Formoterol Fumarate Powder for Inhalation on NF-kappa B pathway in patients with bronchiectasis and its efficacy

FU Hanguang^,

- Department of Emergency, the Second Affiliated Hospital of Hainan Medical University, Haikou, 570311, China

More Information

Corresponding author: FU Hanguang, E-mail: 13876909539@163.com

Received Date: 11 December 2017

摘要

摘要: 目的: 观察布地奈德/福莫特罗吸入剂长期使用对支气管扩张症患者临床疗效以及NF-κB通路的影响。方法: 选取2016-02-2017-12期间我院治疗的支气管扩张症患者142例, 随机分为对照组或观察组, 每组71例。对照组常规治疗, 观察组加用地奈德/福莫特罗吸入剂, 1吸/次, 2次/d, 疗程12周。比较两组临床疗效和不良反应。结果: 治疗前两组诱导痰液中p65、IL-6、TNF-α炎性因子表达和FEV1/FVC、FVE1/pred肺功能指标差异无统计学意义 (P>0.05), 观察组12周疗程结束后p65、IL-6和TNF-α表达显著低于对照组 (P<0.01), FEV1/FVC和FVE1/pred显著高于对照组 (P<0.05)。对照组临床治疗有效率为76.06% (54/71), 显著低于观察组的91.55% (65/71) (P<0.05)。对照组复发率为22.58% (14/62) 显著高于观察组的8.06% (5/62)。治疗期间观察组急性加重 (1.58±0.27) 次, 显著低于对照组的 (2.14±0.46) 次 (P<0.05)。对照组不良反应发生率为7.04% (5/71), 观察组不良反应发生率为8.45% (6/71), 两组不良反应发生率无显著性差异 (P>0.05)。结论: 布地奈德福莫特罗粉吸入剂长期使用可以抑制支气管扩张症患者NF-κB通路, 降低气道局部炎症反应, 减少急性加重次数, 疗效显著, 使用安全。
- 布地奈德福莫特罗粉吸入剂 /
- NF-κB炎性通路 /
- 支气管扩张症
Abstract: Objective: To observe the effect ofBudesonide and FormoterolFumarate Powder for Inhalation on NF-kappa B pathway in patients with bronchiectasis and its efficacy.Method: One hundred and forty-two patients were selected in this study.Patients were divided into:control group (n=71) and observation group (n=71).The control group:conventional therapy.The observation:on the basis of the control group, Budesonide and FormoterolFumarate Powder for Inhalation (2 times/d) was used for 12 weeks.The clinical efficacy and adverse reactions rate was compared.Result: Before treatment, p65, IL-6, TNF-α, FEV1/FVC, and FVE1/predwas no significant difference between the two groups (P>0.05).After treatment, p65, TNF-α, and IL-6 expression in observation group weresignificantly lower than thosein control group (P<0.01), and FEV1/FVC and FVE1/pred in observation group weresignificantly higher than thosein control group (P<0.05).The clinic effective rate in control was76.06% (54/71) which was lower than that of 91.55% (65/71) in observation group (P<0.05).The acute exacerbation times in observation group was 1.58±0.27, which was significantly lower than that of 2.14±0.46 in control group (P<0.05).The adverse reactions rate was 7.04% (5/71) in control group and 8.45% (6/71) in observation group.There was no significant difference between the two groups (P>0.05).Conclusion: Budesonide and FormoterolFumarate Powder for Inhalation can inhibitNF-κB path wayto reduce airway inflammation and times of acute exacerbation, with significant effect and safety.
- Budesonide and FormoterolFumarate Powder for Inhalation /
- NF-κB path way /
- bronchiectasis

HTML全文

参考文献(12)

[1]	钟南山.2017年慢性气道疾病防治研究进展[J].华西医学, 2018, 33 (1):1-7.
[2]	张琼.布地奈德福莫特罗粉吸入剂在稳定期慢性阻塞性肺疾病的临床观察[J].中国药物与临床, 2016, 16 (5):735-737.
[3]	张荣.用布地奈德福莫特罗吸入剂治疗支气管扩张症的效果分析[J].当代医药论丛, 2015, 13 (8):192-193.
[4]	成人支气管扩张症诊治专家共识编写组.成人支气管扩张症诊治专家共识 (2012版)[J].中华危重症医学杂志 (电子版), 2012, 5 (5):315-328.
[5]	梁新, 李荣凯, 宋亚茹.布地奈德福莫特罗粉剂治疗支气管扩张症45例临床分析[J].中国现代药物应用, 2013, 7 (9):138-139.
[6]	杨茂祥, 王红嫚, 王国强, 等.布地奈德联合阿奇霉素治疗慢性阻塞性肺疾病效果及对气道炎症和细菌负荷的影响[J].慢性病学杂志, 2018, 20 (2):159-161.
[7]	Liu K, Zhang X, Zhang J T, et al.Defective CFTR-β-catenin interaction promotes NF-κB nuclear translocation and intestinal inflammation in cystic fibrosis[J].Oncotarget, 2016, 7:64030-64042.
[8]	陈凯, 龚正华, 朱勇.阿奇霉素对支气管扩张患者核因子κB通路的影响以及临床疗效分析[J].药物评价研究, 2018, 41 (2):247-250.
[9]	尹爱明, 贺细梅, 孙凯, 等.小剂量罗红霉素对支气管扩张症NF-κB通路及气道炎症的影响以及临床疗效研究[J].临床肺科杂志, 2016, 21 (11):1955-1957.
[10]	Malcomson B, Wilson H, Veglia E, et al.Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis[J].Proc Natl Acad Sci USA, 2016, 113:E3725-3734.
[11]	Alyasin S, Moghtaderi M, Farjadian S, et al.Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis[J].Electron Physician, 2018, 10:6273-6278.
[12]	Guan W J, Gao Y H, Xu G, et al.Inflammatory Responses, Spirometry, and Quality of Life in Subjects With Bronchiectasis Exacerbations[J].Respir Care, 2015, 60:1180-1189.